U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Oculocutaneous albinism type 1(OCA1A)

MedGen UID:
82809
Concept ID:
C0268494
Disease or Syndrome
Synonyms: Albinism 1; ALBINISM I; OCA1A
SNOMED CT: Oculocutaneous albinism type 1 (765146000); TYR-gene related oculocutaneous albinism type 1 (765146000)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
 
Related gene: TYR
 
Monarch Initiative: MONDO:0018135
OMIM®: 203100
Orphanet: ORPHA352731

Definition

Oculocutaneous albinism is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair, skin, and eyes. The term 'albinism' includes specific ocular changes that are the results of reduced amounts of melanin in the developing eye; these abnormalities in the eye and optic system are specific and necessary for the diagnosis. Aside from decreased pigment in the iris and retina, optic changes include decreased visual acuity, misrouting of the optic nerves at the chiasm, and nystagmus (King et al., 2001). Although OCA caused by mutations in the TYR gene was classically known as 'tyrosinase-negative' OCA, Tripathi et al. (1992) noted that some patients with 'tyrosinase-positive' OCA may indeed have TYR mutations resulting in residual enzyme activity. These patients can be classified as having OCA1B. Genetic Heterogeneity of Oculocutaneous Albinism OCA1, caused by mutations in the TYR gene, is divided clinically into 2 types: type IA, OCA1A, characterized by complete lack of tyrosinase activity due to production of an inactive enzyme, and type IB (OCA1B; 606952), characterized by reduced activity of tyrosinase. OCA2 (203200), OCA3 (203290), and OCA4 (606574) are somewhat milder forms of the disorder, caused by mutations in the OCA2 (611409), TYRP1 (115501), and MATP (SLC45A2; 606202) genes, respectively. OCA5 (615312) has been mapped to chromosome 4q24. OCA6 (see 113750) is caused by mutation in the SLC24A5 gene (609802). OCA7 (615179) is caused by mutation in the LRMDA gene (614537). OCA8 (619165) is caused by mutation in the DCT gene (191275). See also ocular albinism (OA1; 300500), which is restricted phenotypically to ocular involvement only. [from OMIM]

Additional description

From MedlinePlus Genetics
There are several additional, rare types of oculocutaneous albinism.

Oculocutaneous albinism also reduces pigmentation of the colored part of the eye (the iris) and the light-sensitive tissue at the back of the eye (the retina). People with this condition usually have vision problems such as reduced sharpness; rapid, involuntary eye movements (nystagmus); eyes that do not point in the same direction (strabismus); and increased sensitivity to light (photophobia).

Oculocutaneous albinism is a group of conditions that affect the color of (pigmentation) of the skin, hair, and eyes. Affected individuals typically have very fair skin and white or light-colored hair. Long-term sun exposure greatly increases the risk of skin damage and skin cancers, including an aggressive form of skin cancer called melanoma, in people with this condition. 

Researchers have identified multiple types of oculocutaneous albinism, which are distinguished by their specific skin, hair, and eye color changes, and by their genetic cause. Oculocutaneous albinism type 1 is characterized by white hair, very pale skin, and light-colored irises. Type 2 is typically less severe than type 1; the skin is usually pale and hair may be light yellow, blond, or light brown. Type 3 causes reddish-brown skin, ginger or red hair, and hazel or brown irises. Type 3 is often associated with milder vision abnormalities than the other forms of oculocutaneous albinism. Type 4 has signs and symptoms similar to those seen in people with type 2.  https://medlineplus.gov/genetics/condition/oculocutaneous-albinism

Professional guidelines

PubMed

Mondal M, Sengupta M, Ray K
Br J Dermatol 2016 Dec;175(6):1232-1242. Epub 2016 Nov 11 doi: 10.1111/bjd.14977. PMID: 27537549
Santiago Borrero PJ, Rodríguez-Pérez Y, Renta JY, Izquierdo NJ, Del Fierro L, Muñoz D, Molina NL, Ramírez S, Pagán-Mercado G, Ortíz I, Rivera-Caragol E, Spritz RA, Cadilla CL
J Invest Dermatol 2006 Jan;126(1):85-90. doi: 10.1038/sj.jid.5700034. PMID: 16417222Free PMC Article

Recent clinical studies

Etiology

Li C, Chen Q, Wu J, Ren J, Zhang M, Wang H, Li J, Tang Y
J Biol Chem 2022 May;298(5):101922. Epub 2022 Apr 10 doi: 10.1016/j.jbc.2022.101922. PMID: 35413289Free PMC Article
Kruijt CC, Gradstein L, Bergen AA, Florijn RJ, Arveiler B, Lasseaux E, Zanlonghi X, Bagdonaite-Bejarano L, Fulton AB, Yahalom C, Blumenfeld A, Perez Y, Birk OS, de Wit GC, Schalij-Delfos NE, van Genderen MM
Invest Ophthalmol Vis Sci 2022 Jan 3;63(1):19. doi: 10.1167/iovs.63.1.19. PMID: 35029636Free PMC Article
May L, Merrill K, Connett JE, Summers CG
J Binocul Vis Ocul Motil 2021 Jan-Mar;71(1):1-6. Epub 2021 Jan 20 doi: 10.1080/2576117X.2020.1856609. PMID: 33470906
Lu Q, Yuan L, Xu H, Huang X, Yang Z, Yi J, Ni B, Chen Y, Deng H
Mol Med Rep 2017 Mar;15(3):1426-1430. Epub 2017 Jan 23 doi: 10.3892/mmr.2017.6137. PMID: 28112372
Ghodsinejad Kalahroudi V, Kamalidehghan B, Arasteh Kani A, Aryani O, Tondar M, Ahmadipour F, Chung LY, Houshmand M
PLoS One 2014;9(9):e106656. Epub 2014 Sep 12 doi: 10.1371/journal.pone.0106656. PMID: 25216246Free PMC Article

Diagnosis

Diallo M, Sylla O, Sidibé MK, Plaisant C, Mercier E, Sequeira A, Javerzat S, Hadid A, Lasseaux E, Michaud V, Arveiler B
Pigment Cell Melanoma Res 2024 Nov;37(6):752-761. Epub 2024 May 9 doi: 10.1111/pcmr.13175. PMID: 38720644
Si S, Jia X, Xu L, Qin Q, Wu J, Ji W, Dong K, Zhang X, Cao L, Wang H, Liu P, Wang R, Bai J, Fu S, Huang Y, Sun W
Pigment Cell Melanoma Res 2023 Nov;36(6):472-480. Epub 2023 Jul 5 doi: 10.1111/pcmr.13111. PMID: 37403904
Kruijt CC, Gradstein L, Bergen AA, Florijn RJ, Arveiler B, Lasseaux E, Zanlonghi X, Bagdonaite-Bejarano L, Fulton AB, Yahalom C, Blumenfeld A, Perez Y, Birk OS, de Wit GC, Schalij-Delfos NE, van Genderen MM
Invest Ophthalmol Vis Sci 2022 Jan 3;63(1):19. doi: 10.1167/iovs.63.1.19. PMID: 35029636Free PMC Article
May L, Merrill K, Connett JE, Summers CG
J Binocul Vis Ocul Motil 2021 Jan-Mar;71(1):1-6. Epub 2021 Jan 20 doi: 10.1080/2576117X.2020.1856609. PMID: 33470906
Oetting WS, Fryer JP, Shriram S, King RA
Pigment Cell Res 2003 Jun;16(3):307-11. doi: 10.1034/j.1600-0749.2003.00045.x. PMID: 12753405

Therapy

Teramae A, Kobayashi Y, Kunimoto H, Nakajima K, Suzuki T, Tsuruta D, Fukai K
J Invest Dermatol 2019 May;139(5):1143-1149. Epub 2018 Nov 14 doi: 10.1016/j.jid.2018.10.033. PMID: 30447237
Kus NJ, Dolinska MB, Young KL 2nd, Dimitriadis EK, Wingfield PT, Sergeev YV
PLoS One 2018;13(6):e0198247. Epub 2018 Jun 5 doi: 10.1371/journal.pone.0198247. PMID: 29870551Free PMC Article
Onojafe IF, Adams DR, Simeonov DR, Zhang J, Chan CC, Bernardini IM, Sergeev YV, Dolinska MB, Alur RP, Brilliant MH, Gahl WA, Brooks BP
J Clin Invest 2011 Oct;121(10):3914-23. doi: 10.1172/JCI59372. PMID: 21968110Free PMC Article

Prognosis

Si S, Jia X, Xu L, Qin Q, Wu J, Ji W, Dong K, Zhang X, Cao L, Wang H, Liu P, Wang R, Bai J, Fu S, Huang Y, Sun W
Pigment Cell Melanoma Res 2023 Nov;36(6):472-480. Epub 2023 Jul 5 doi: 10.1111/pcmr.13111. PMID: 37403904
Kruijt CC, Gradstein L, Bergen AA, Florijn RJ, Arveiler B, Lasseaux E, Zanlonghi X, Bagdonaite-Bejarano L, Fulton AB, Yahalom C, Blumenfeld A, Perez Y, Birk OS, de Wit GC, Schalij-Delfos NE, van Genderen MM
Invest Ophthalmol Vis Sci 2022 Jan 3;63(1):19. doi: 10.1167/iovs.63.1.19. PMID: 35029636Free PMC Article
Ghodsinejad Kalahroudi V, Kamalidehghan B, Arasteh Kani A, Aryani O, Tondar M, Ahmadipour F, Chung LY, Houshmand M
PLoS One 2014;9(9):e106656. Epub 2014 Sep 12 doi: 10.1371/journal.pone.0106656. PMID: 25216246Free PMC Article
Liu J, Choy KW, Chan LW, Leung TY, Tam PO, Chiang SW, Lam DS, Pang CP, Lai TY
Clin Exp Ophthalmol 2010 Jan;38(1):37-42. doi: 10.1111/j.1442-9071.2009.02220.x. PMID: 20447099
Harvey PS, King RA, Summers CG
J AAPOS 2006 Jun;10(3):237-42. doi: 10.1016/j.jaapos.2006.01.008. PMID: 16814177

Clinical prediction guides

Woods T, Sergeev YV
Int J Mol Sci 2023 Aug 22;24(17) doi: 10.3390/ijms241713032. PMID: 37685839Free PMC Article
Si S, Jia X, Xu L, Qin Q, Wu J, Ji W, Dong K, Zhang X, Cao L, Wang H, Liu P, Wang R, Bai J, Fu S, Huang Y, Sun W
Pigment Cell Melanoma Res 2023 Nov;36(6):472-480. Epub 2023 Jul 5 doi: 10.1111/pcmr.13111. PMID: 37403904
Monfermé S, Lasseaux E, Duncombe-Poulet C, Hamel C, Defoort-Dhellemmes S, Drumare I, Zanlonghi X, Dollfus H, Perdomo Y, Bonneau D, Korobelnik JF, Plaisant C, Michaud V, Pennamen P, Rooryck-Thambo C, Morice-Picard F, Paya C, Arveiler B
Br J Ophthalmol 2019 Sep;103(9):1239-1247. Epub 2018 Nov 24 doi: 10.1136/bjophthalmol-2018-312729. PMID: 30472657
Ghodsinejad Kalahroudi V, Kamalidehghan B, Arasteh Kani A, Aryani O, Tondar M, Ahmadipour F, Chung LY, Houshmand M
PLoS One 2014;9(9):e106656. Epub 2014 Sep 12 doi: 10.1371/journal.pone.0106656. PMID: 25216246Free PMC Article
Liu J, Choy KW, Chan LW, Leung TY, Tam PO, Chiang SW, Lam DS, Pang CP, Lai TY
Clin Exp Ophthalmol 2010 Jan;38(1):37-42. doi: 10.1111/j.1442-9071.2009.02220.x. PMID: 20447099

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...